11:45-12:45

Session 1: Illuminating the challenge and highlighting the opportunity for creating new medicines
Chair: Adrian Carter

Illuminating the Druggable Genome with Informatics, Data Science and Machine Learning 
Tudor Oprea - University of New Mexico, USA

Functionalization of the human protein-coding genome to discover medicines for neurodegenerative disease
Heiko Runz - Biogen, USA

Chemical probes and the chemical biology of cancer
Paul Workman - CRUK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK

Coffee break

Session 2: Illuminating the most promising proteins by virtue of druggability, human genetics and bioinformatics
Chair: Patrick Aloy

Computational identification of drug targets in cancer
Eytan Ruppin - National Cancer Institute, USA

Proteome-wide identification of new druggable targets for antibiotics
Stephan Hacker - Technical University of Munich, Germany

Target Tractability: Making full use of protein homology
Kristin Brown - GlaxoSmithKline, UK

Epigenetic variation across individuals to understand disease mechanisms
Judith Zaugg - EMBL Heidelberg, Germany

Extending the small molecule similarity principle to all levels of biology 
Patrick Aloy - IRB Barcelona, Spain

Poster Session 1 (odd numbers)
with beer and snacks, ATC Helix A

Poster Session 2  (even numbers)
with beer and snacks, ATC Helix A

Dinner
EMBL Canteen

Session 3: Interrogating the druggable proteome with chemical probes, imaging and sensor proteins, part 1
Chair: Gerard Drewes

Shaping biology by modulating access to chemical matter
Giulio Superti-Furga - CeMM Research Centre for Molecular Medicine/ Medical University of Vienna, Austria

The target landscape of 1,200 kinase inhibitors
Maria Reinecke - Technical University of Munich/ DKTK partner site Munich, Germany

Covalent inhibitors for 'undruggable' targets
Nir London - The Weizman Institute of Science, Israel

Targeting protein scaffolding function in kinases
Stefan Knapp - Goethe University Frankfurt, Germany

Coffee break

Exploring the druggable proteome by image-based phenotyping in cell lines and patient derived organoids 
Michael Boutros - German Cancer Research Centre/ Heidelberg University, Germany

Mechanisms of intracellular DNA sensing through the cGAS-STING pathway
Andrea Ablasser - EPFL, Switzerland

Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN
Georg Petzold - Friedrich Miescher Institute for Biomedical Research, Switzerland

Stabilization of protein-protein interactions
Pim de Vink - Eindhoven University of Technology, The Netherlands

Lunch and meet the speakers

Session 4: Interrogating the druggable proteome with chemical probes, imaging and sensor proteins, part 2
Chair: Anke Müller-Fahrnow

Tetrahydrobiopterin homeostasis
Kai Johnsson - Max Planck Institute for Medical Research, Germany 

Chemical physiology of natural products and antibody conjugates
Gonçalo Bernardes - University of Cambridge, UK and iMM Lisboa, Portugal

Within our control? Leveraging precision electrophile signaling toward drug discovery
Yimon Aye - EPFL, Switzerland

Understanding cellular phenotypes; from screens to probes towards clinical candidates
Marcus Bauser - Bayer AG, Germany

Coffee break

A systems approach to functional precision medicine by deep learning and multi-OMICs
Berend Snijder - ETH Zürich, Switzerland

Mapping genetic networks using functional and chemical genomics
Brenda Andrews - University of Toronto, Canada

Biophysical screening of combinatorial libraries to target protein-protein interactions with covalent agents
Maurizio Pellecchia - University of California, Riverside, USA

NanoBRET cellular target engagement assays are versatile in enabling drug screening for various proteins – the SGC experience
Benedict Berger - Structural Genomics Consortium, Goethe University Frankfurt, Germany

Chemical biology at the interface of discovery to deliver novel to targets to the Drug Discovery Pipeline
Christine Donahue - GlaxoSmithKline, USA

Coffee break

Session 7: New engineering approaches for breaking the druggability barrier
Chair: Katrin Rittinger

Targeting the active site of E3 ligases with chemical tools
Katrin Rittinger - The Francis Crick Institute, UK

Structure based PROTAC design to expand the druggable proteome
Alessio Ciulli - University of Dundee, UK

Chemical probes in target discovery
Paul Brennan - University of Oxford, UK

Identification of microbiome-encoded enzymes involved in drug metabolism
Michael Zimmermann - EMBL Heidelberg, Germany

End of conference
Packed lunch and departure

Bus departure all stops downtown

Bus to Frankfurt Intl. Airport